Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial

B Ejlertsen; J Aldridge; K V Nielsen; M M Regan; K L Henriksen; Anne Lykkesfeldt; S Müller; R D Gelber; K N Price; B B Rasmussen; G Viale; H Mouridsen; for the Danish Breast Cancer Cooperative Group, the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group

doi:10.1093/annonc/mdr438

Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial

B Ejlertsen, J Aldridge, K V Nielsen, M M Regan, K L Henriksen, Anne Lykkesfeldt, S Müller, R D Gelber, K N Price, B B Rasmussen, G Viale, H Mouridsen, for the Danish Breast Cancer Cooperative Group, the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group

Patologiafdeling HGH

18 Citationer (Scopus)

Abstract

BACKGROUND: Estrogen Receptor 1 (ESR1) aberrations may be associated with expression of estrogen receptor (ER) or progesterone receptor (PgR), human epidermal growth factor receptor-2 (HER2) or Ki-67 labeling index and prognosis. PATIENTS AND METHODS: ESR1 was assessed in 1129 (81%) of 1396 postmenopausal Danish women with early breast cancer randomly assigned to receive 5 years of letrozole, tamoxifen or a sequence of these agents in the Breast International Group 1-98 trial and who had ER ≥1% after central review. RESULTS: By FISH, 13.6% of patients had an ESR1-to-Centromere-6 (CEN-6) ratio ≥2 (amplified), and 4.2% had ESR1-to-CEN-6 ratio

Originalsprog	Engelsk
Tidsskrift	Annals of Oncology
Vol/bind	23
Udgave nummer	5
Sider (fra-til)	1138-1144
ISSN	0923-7534
DOI	https://doi.org/10.1093/annonc/mdr438
Status	Udgivet - 10 okt. 2012

Adgang til dokumentet

10.1093/annonc/mdr438

Citationsformater

Ejlertsen, B., Aldridge, J., Nielsen, K. V., Regan, M. M., Henriksen, K. L., Lykkesfeldt, A., Müller, S., Gelber, R. D., Price, K. N., Rasmussen, B. B., Viale, G., Mouridsen, H., & for the Danish Breast Cancer Cooperative Group, the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group (2012). Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Annals of Oncology, 23(5), 1138-1144. https://doi.org/10.1093/annonc/mdr438

Ejlertsen, B, Aldridge, J, Nielsen, KV, Regan, MM, Henriksen, KL, Lykkesfeldt, A, Müller, S, Gelber, RD, Price, KN, Rasmussen, BB, Viale, G, Mouridsen, H & for the Danish Breast Cancer Cooperative Group, the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group 2012, 'Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial', Annals of Oncology, bind 23, nr. 5, s. 1138-1144. https://doi.org/10.1093/annonc/mdr438

@article{220be82ef5af4179bb3f3d3bb37039a2,

title = "Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial",

abstract = "BACKGROUND: Estrogen Receptor 1 (ESR1) aberrations may be associated with expression of estrogen receptor (ER) or progesterone receptor (PgR), human epidermal growth factor receptor-2 (HER2) or Ki-67 labeling index and prognosis. PATIENTS AND METHODS: ESR1 was assessed in 1129 (81%) of 1396 postmenopausal Danish women with early breast cancer randomly assigned to receive 5 years of letrozole, tamoxifen or a sequence of these agents in the Breast International Group 1-98 trial and who had ER ≥1% after central review. RESULTS: By FISH, 13.6% of patients had an ESR1-to-Centromere-6 (CEN-6) ratio ≥2 (amplified), and 4.2% had ESR1-to-CEN-6 ratio ",

author = "B Ejlertsen and J Aldridge and Nielsen, {K V} and Regan, {M M} and Henriksen, {K L} and Anne Lykkesfeldt and S M{\"u}ller and Gelber, {R D} and Price, {K N} and Rasmussen, {B B} and G Viale and H Mouridsen and {for the Danish Breast Cancer Cooperative Group, the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group}",

year = "2012",

month = oct,

day = "10",

doi = "10.1093/annonc/mdr438",

language = "English",

volume = "23",

pages = "1138--1144",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Limited",

number = "5",

}

TY - JOUR

T1 - Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial

AU - Ejlertsen, B

AU - Aldridge, J

AU - Nielsen, K V

AU - Regan, M M

AU - Henriksen, K L

AU - Lykkesfeldt, Anne

AU - Müller, S

AU - Gelber, R D

AU - Price, K N

AU - Rasmussen, B B

AU - Viale, G

AU - Mouridsen, H

AU - for the Danish Breast Cancer Cooperative Group, the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group

PY - 2012/10/10

Y1 - 2012/10/10

N2 - BACKGROUND: Estrogen Receptor 1 (ESR1) aberrations may be associated with expression of estrogen receptor (ER) or progesterone receptor (PgR), human epidermal growth factor receptor-2 (HER2) or Ki-67 labeling index and prognosis. PATIENTS AND METHODS: ESR1 was assessed in 1129 (81%) of 1396 postmenopausal Danish women with early breast cancer randomly assigned to receive 5 years of letrozole, tamoxifen or a sequence of these agents in the Breast International Group 1-98 trial and who had ER ≥1% after central review. RESULTS: By FISH, 13.6% of patients had an ESR1-to-Centromere-6 (CEN-6) ratio ≥2 (amplified), and 4.2% had ESR1-to-CEN-6 ratio

AB - BACKGROUND: Estrogen Receptor 1 (ESR1) aberrations may be associated with expression of estrogen receptor (ER) or progesterone receptor (PgR), human epidermal growth factor receptor-2 (HER2) or Ki-67 labeling index and prognosis. PATIENTS AND METHODS: ESR1 was assessed in 1129 (81%) of 1396 postmenopausal Danish women with early breast cancer randomly assigned to receive 5 years of letrozole, tamoxifen or a sequence of these agents in the Breast International Group 1-98 trial and who had ER ≥1% after central review. RESULTS: By FISH, 13.6% of patients had an ESR1-to-Centromere-6 (CEN-6) ratio ≥2 (amplified), and 4.2% had ESR1-to-CEN-6 ratio

U2 - 10.1093/annonc/mdr438

DO - 10.1093/annonc/mdr438

M3 - Journal article

C2 - 21986093

SN - 0923-7534

VL - 23

SP - 1138

EP - 1144

JO - Annals of Oncology

JF - Annals of Oncology

IS - 5

ER -

Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater